CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: EC 2.5.1.15 (dihydropteroate synthase) inhibitor
Accession: CHEBI:50502
browse the term
Definition: An EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of dihydropteroate synthase (EC 2.5.1.15), an enzyme that catalyzes the formation of dihydropteroate from p-aminobenzoic acid and dihydropteridine-hydroxymethyl-pyrophosphate.
Synonyms: related_synonym: (2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitor; (2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitors; 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitor; 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitors; 7,8-dihydropteroate synthase inhibitor; 7,8-dihydropteroate synthase inhibitors; 7,8-dihydropteroate synthetase inhibitor; 7,8-dihydropteroate synthetase inhibitors; 7,8-dihydropteroic acid synthetase inhibitor; 7,8-dihydropteroic acid synthetase inhibitors; DHPS inhibitor; DHPS inhibitors; EC 2.5.1.15 (dihydropteroate synthase) inhibitors; EC 2.5.1.15 inhibitor; EC 2.5.1.15 inhibitors; dihydropteroate diphosphorylase inhibitor; dihydropteroate diphosphorylase inhibitors; dihydropteroate pyrophosphorylase inhibitor; dihydropteroate pyrophosphorylase inhibitors; dihydropteroate synthase inhibitor; dihydropteroate synthase inhibitors; dihydropteroate synthetase inhibitor; dihydropteroate synthetase inhibitors; dihydropteroic synthetase inhibitor; dihydropteroic synthetase inhibitors
xref: Wikipedia:Dihydropteroate_synthase_inhibitor
G
INS
insulin
increases secretion
EXP
Trimethoprim, Sulfamethoxazole Drug Combination results in increased secretion of INS protein modified form
CTD
PMID:14714756
NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221
G
DDIT4
DNA damage inducible transcript 4
multiple interactions increases expression
ISO
[Folic Acid deficiency co-treated with succinylsulfathiazole] results in decreased expression of DDIT4 protein succinylsulfathiazole results in increased expression of DDIT4 protein
CTD
PMID:33957263
NCBI chr10:72,273,924...72,276,036
Ensembl chr10:72,273,919...72,276,036
G
EIF4EBP1
eukaryotic translation initiation factor 4E binding protein 1
decreases phosphorylation
ISO
succinylsulfathiazole results in decreased phosphorylation of EIF4EBP1 protein
CTD
PMID:33957263
NCBI chr 8:38,030,534...38,060,365
Ensembl chr 8:38,030,534...38,060,365
G
MTOR
mechanistic target of rapamycin kinase
decreases phosphorylation
ISO
succinylsulfathiazole results in decreased phosphorylation of MTOR protein
CTD
PMID:33957263
NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556
G
PDPK1
3-phosphoinositide dependent protein kinase 1
decreases expression multiple interactions
ISO
succinylsulfathiazole results in decreased expression of PDPK1 protein Folic Acid deficiency inhibits the reaction [succinylsulfathiazole results in decreased expression of PDPK1 protein]
CTD
PMID:33957263
NCBI chr16:2,538,021...2,603,188
Ensembl chr16:2,537,979...2,603,188
G
AKR1B10
aldo-keto reductase family 1 member B10
increases expression
EXP
4-nitrososulfamethoxazole results in increased expression of AKR1B10 mRNA
CTD
PMID:28444390
NCBI chr 7:134,527,567...134,541,412
Ensembl chr 7:134,527,567...134,541,412
G
HMGB1
high mobility group box 1
increases secretion
EXP
4-nitrososulfamethoxazole results in increased secretion of HMGB1 protein
CTD
PMID:28444390
NCBI chr13:30,456,704...30,617,597
Ensembl chr13:30,456,704...30,617,597
G
IFNG
interferon gamma
increases secretion
EXP
4-nitrososulfamethoxazole results in increased secretion of IFNG protein
CTD
PMID:22331489
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
G
IL13
interleukin 13
increases secretion
EXP
4-nitrososulfamethoxazole results in increased secretion of IL13 protein
CTD
PMID:22331489
NCBI chr 5:132,656,522...132,661,110
Ensembl chr 5:132,656,263...132,661,110
G
IL1A
interleukin 1 alpha
increases secretion
EXP
4-nitrososulfamethoxazole results in increased secretion of IL1A protein
CTD
PMID:28444390
NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493
G
IL1B
interleukin 1 beta
increases secretion
EXP
4-nitrososulfamethoxazole results in increased secretion of IL1B protein
CTD
PMID:28444390
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
G
IL5
interleukin 5
increases secretion
EXP
4-nitrososulfamethoxazole results in increased secretion of IL5 protein
CTD
PMID:22331489
NCBI chr 5:132,541,445...132,556,815
Ensembl chr 5:132,541,445...132,556,838
G
IL6
interleukin 6
increases secretion
EXP
4-nitrososulfamethoxazole results in increased secretion of IL6 protein
CTD
PMID:28444390
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
G
MPO
myeloperoxidase
affects binding multiple interactions
EXP
4-nitrososulfamethoxazole binds to MPO protein [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Sulfamethoxazole] which results in increased chemical synthesis of 4-nitrososulfamethoxazole
CTD
PMID:25531135
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
G
NQO1
NAD(P)H quinone dehydrogenase 1
increases expression
EXP
4-nitrososulfamethoxazole results in increased expression of NQO1 mRNA
CTD
PMID:28444390
NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
G
SRXN1
sulfiredoxin 1
increases expression
EXP
4-nitrososulfamethoxazole results in increased expression of SRXN1 mRNA
CTD
PMID:28444390
NCBI chr20:646,615...653,200
Ensembl chr20:646,615...653,200
G
TNF
tumor necrosis factor
increases secretion
EXP
4-nitrososulfamethoxazole results in increased secretion of TNF protein
CTD
PMID:28444390
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
G
TXNRD1
thioredoxin reductase 1
increases expression
EXP
4-nitrososulfamethoxazole results in increased expression of TXNRD1 mRNA
CTD
PMID:28444390
NCBI chr12:104,215,779...104,350,307
Ensembl chr12:104,215,779...104,350,307
G
HMBS
hydroxymethylbilane synthase
decreases activity
ISO
Sulfacetamide decreases activity of purified Hmbs protein
RGD
PMID:6893114
RGD:26923963
NCBI chr11:119,084,881...119,093,549
Ensembl chr11:119,084,866...119,093,834
G
CYP2C8
cytochrome P450 family 2 subfamily C member 8
increases hydroxylation
EXP
CYP2C8 protein results in increased hydroxylation of Sulfadiazine
CTD
PMID:15843491
NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497
G
CYP2C9
cytochrome P450 family 2 subfamily C member 9
increases hydroxylation
EXP
CYP2C9 protein results in increased hydroxylation of Sulfadiazine
CTD
PMID:15843491
NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
G
GRIN1
glutamate ionotropic receptor NMDA type subunit 1
decreases expression
EXP
Sulfadiazine results in decreased expression of GRIN1 mRNA
CTD
PMID:34748853
NCBI chr 9:137,139,154...137,168,756
Ensembl chr 9:137,138,346...137,168,756
G
HMBS
hydroxymethylbilane synthase
decreases activity
ISO
Sulfadiazine decreases activity of purified Hmbs protein
RGD
PMID:6893114
RGD:26923963
NCBI chr11:119,084,881...119,093,549
Ensembl chr11:119,084,866...119,093,834
G
IL6
interleukin 6
multiple interactions
EXP
[Sulfadiazine co-treated with Pyrimethamine] results in decreased expression of IL6 protein; [Trimethoprim co-treated with Sulfadiazine] results in increased expression of IL6 protein
CTD
PMID:10888991 PMID:37722575
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
G
LPO
lactoperoxidase
decreases expression
EXP
Sulfadiazine results in decreased expression of LPO mRNA
CTD
PMID:34748853
NCBI chr17:58,238,584...58,268,518
Ensembl chr17:58,218,548...58,268,518
G
MTOR
mechanistic target of rapamycin kinase
decreases expression
EXP
Sulfadiazine results in decreased expression of MTOR mRNA
CTD
PMID:34748853
NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556
G
NAT2
N-acetyltransferase 2
increases acetylation
EXP
NAT2 protein results in increased acetylation of Sulfadiazine
CTD
PMID:15843491
NCBI chr 8:18,386,301...18,401,218
Ensembl chr 8:18,391,282...18,401,218
G
OLIG2
oligodendrocyte transcription factor 2
decreases expression
EXP
Sulfadiazine results in decreased expression of OLIG2 mRNA
CTD
PMID:34748853
NCBI chr21:33,025,935...33,029,185
Ensembl chr21:33,025,935...33,029,196
G
SHANK2
SH3 and multiple ankyrin repeat domains 2
decreases expression
EXP
Sulfadiazine results in decreased expression of SHANK2 mRNA
CTD
PMID:34748853
NCBI chr11:70,467,854...71,253,228
Ensembl chr11:70,467,854...71,252,577
G
SLC6A4
solute carrier family 6 member 4
decreases expression
EXP
Sulfadiazine results in decreased expression of SLC6A4 mRNA
CTD
PMID:34748853
NCBI chr17:30,194,319...30,235,697
Ensembl chr17:30,194,319...30,236,002
G
CYP3A4
cytochrome P450 family 3 subfamily A member 4
increases activity
EXP
Sulfamethazine results in increased activity of CYP3A4 protein
CTD
PMID:12065438
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
G
NAT2
N-acetyltransferase 2
increases acetylation increases metabolic processing affects acetylation
EXP
NAT2 protein results in increased acetylation of Sulfamethazine NAT2 protein results in increased metabolism of Sulfamethazine NAT2 polymorphism affects the acetylation of Sulfamethazine
CTD
PMID:12222688 PMID:15627487 PMID:15880531 PMID:21317369 PMID:28516247 PMID:30358977 More...
NCBI chr 8:18,386,301...18,401,218
Ensembl chr 8:18,391,282...18,401,218
G
NR1I2
nuclear receptor subfamily 1 group I member 2
increases activity
EXP
Sulfamethazine results in increased activity of NR1I2 protein
CTD
PMID:12065438
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
G
IL1B
interleukin 1 beta
multiple interactions
ISO
Sulfamethizole inhibits the reaction [Poloxalene results in increased expression of IL1B protein]
CTD
PMID:36799065
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
G
MTOR
mechanistic target of rapamycin kinase
multiple interactions
ISO
Sulfamethizole inhibits the reaction [Poloxalene results in increased expression of MTOR protein]
CTD
PMID:36799065
NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556
G
TNF
tumor necrosis factor
multiple interactions
ISO
Sulfamethizole inhibits the reaction [Poloxalene results in increased expression of TNF protein]
CTD
PMID:36799065
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
G
ABCB11
ATP binding cassette subfamily B member 11
decreases activity multiple interactions
EXP
Sulfamethoxazole results in decreased activity of ABCB11 protein Sulfamethoxazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
CTD
PMID:24014644
NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324
G
ACAN
aggrecan
decreases expression
ISO
Sulfamethoxazole results in decreased expression of ACAN mRNA
CTD
PMID:26107568
NCBI chr15:88,803,436...88,875,353
Ensembl chr15:88,803,436...88,875,353
G
ALB
albumin
multiple interactions
EXP
Sulfamethoxazole metabolite binds to and results in increased metabolism of ALB protein
CTD
PMID:19358516
NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482
G
COL2A1
collagen type II alpha 1 chain
decreases expression
ISO
Sulfamethoxazole results in decreased expression of COL2A1 mRNA
CTD
PMID:26107568
NCBI chr12:47,972,967...48,006,212
Ensembl chr12:47,972,967...48,004,554
G
CXCL8
C-X-C motif chemokine ligand 8
increases secretion
EXP
Sulfamethoxazole results in increased secretion of CXCL8 protein
CTD
PMID:22609641
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
G
CYP3A4
cytochrome P450 family 3 subfamily A member 4
multiple interactions
ISO
[SOD2 co-treated with CYP3A4] affects the susceptibility to Sulfamethoxazole
CTD
PMID:19501153
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
G
GSTP1
glutathione S-transferase pi 1
multiple interactions
EXP
Sulfamethoxazole metabolite binds to and results in increased metabolism of GSTP1 protein
CTD
PMID:19358516
NCBI chr11:67,583,812...67,586,653
Ensembl chr11:67,583,742...67,586,656
G
HLA-G
major histocompatibility complex, class I, G
affects expression
EXP
Sulfamethoxazole affects the expression of HLA-G mRNA
CTD
PMID:25811541
NCBI chr 6:29,826,474...29,831,021
Ensembl chr 6:29,826,967...29,831,125
G
IFNG
interferon gamma
increases secretion
ISO
Sulfamethoxazole analog results in increased secretion of IFNG protein
CTD
PMID:15588915
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
G
IL5
interleukin 5
increases secretion
ISO
Sulfamethoxazole analog results in increased secretion of IL5 protein
CTD
PMID:15588915
NCBI chr 5:132,541,445...132,556,815
Ensembl chr 5:132,541,445...132,556,838
G
MIR155
microRNA 155
increases expression
EXP
Sulfamethoxazole results in increased expression of MIR155 mRNA
CTD
PMID:29644860
NCBI chr21:25,573,980...25,574,044
Ensembl chr21:25,573,980...25,574,044
G
MIR18A
microRNA 18a
increases expression
EXP
Sulfamethoxazole results in increased expression of MIR18A mRNA
CTD
PMID:29644860
NCBI chr13:91,350,751...91,350,821
Ensembl chr13:91,350,751...91,350,821
G
MIR21
microRNA 21
increases expression
EXP
Sulfamethoxazole results in increased expression of MIR21 mRNA
CTD
PMID:29644860
NCBI chr17:59,841,266...59,841,337
Ensembl chr17:59,841,266...59,841,337
G
MPO
myeloperoxidase
multiple interactions
EXP
[[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Sulfamethoxazole] which results in increased chemical synthesis of 4-nitrososulfamethoxazole; [MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Sulfamethoxazole
CTD
PMID:25531135
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
G
NAT2
N-acetyltransferase 2
increases metabolic processing
EXP
NAT2 protein results in increased metabolism of Sulfamethoxazole
CTD
PMID:16847467
NCBI chr 8:18,386,301...18,401,218
Ensembl chr 8:18,391,282...18,401,218
G
PHYH
phytanoyl-CoA 2-hydroxylase
decreases expression
EXP
Sulfamethoxazole results in decreased expression of PHYH mRNA
CTD
PMID:15342952
NCBI chr10:13,277,799...13,300,064
Ensembl chr10:13,277,796...13,302,412
G
PIR
pirin
increases expression
EXP
Sulfamethoxazole results in increased expression of PIR mRNA
CTD
PMID:22609641
NCBI chr X:15,384,799...15,493,333
Ensembl chr X:15,384,799...15,493,564
G
SOD2
superoxide dismutase 2
multiple interactions
ISO
[SOD2 co-treated with CYP3A4] affects the susceptibility to Sulfamethoxazole
CTD
PMID:19501153
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
G
SOX9
SRY-box transcription factor 9
decreases expression
ISO
Sulfamethoxazole results in decreased expression of SOX9 mRNA
CTD
PMID:26107568
NCBI chr17:72,121,020...72,126,416
Ensembl chr17:72,121,020...72,126,416
G
CYB5B
cytochrome b5 type B
multiple interactions
EXP
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine
CTD
PMID:25170804
NCBI chr16:69,424,619...69,466,264
Ensembl chr16:69,398,402...69,466,264
G
CYB5R3
cytochrome b5 reductase 3
multiple interactions
EXP
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine
CTD
PMID:25170804
NCBI chr22:42,617,840...42,649,392
Ensembl chr22:42,615,730...42,720,870
G
MTARC1
mitochondrial amidoxime reducing component 1
multiple interactions
EXP
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine
CTD
PMID:25170804
NCBI chr 1:220,786,913...220,819,659
Ensembl chr 1:220,786,352...220,819,659
G
MTARC2
mitochondrial amidoxime reducing component 2
multiple interactions
EXP
[MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine
CTD
PMID:25170804
NCBI chr 1:220,748,322...220,784,815
Ensembl chr 1:220,748,225...220,784,815
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all